The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Recent advances in extracellular vesicles for therapeutic cargo delivery
Abstract
Exosomes, which are nanosized vesicles secreted by cells, are attracting increasing interest in the field of biomedical research due to their unique properties, including biocompatibility, cargo loading capacity, and deep tissue penetration. They serve as natural signaling agents in intercellular communication, and their inherent ability to carry proteins, lipids, and nucleic acids endows them with remarkable therapeutic potential. Thus, exosomes can be exploited for diverse therapeutic applications, including chemotherapy, gene therapy, and photothermal therapy. Moreover, their capacity for homotypic targeting and self-recognition provides opportunities for personalized medicine. Despite their advantages as novel therapeutic agents, there are several challenges in optimizing cargo loading efficiency and structural stability and in defining exosome origins. Future research should include the development of large-scale, quality-controllable production methods, the refinement of drug loading strategies, and extensive in vivo studies and clinical trials. Despite the unresolved difficulties, the use of exosomes as efficient, stable, and safe therapeutic delivery systems is an interesting area in biomedical research. Therefore, this review describes exosomes and summarizes cutting-edge studies published in high-impact journals that have introduced novel or enhanced therapeutic effects using exosomes as a drug delivery system in the past 2 years. We provide an informative overview of the current state of exosome research, highlighting the unique properties and therapeutic applications of exosomes. We also emphasize challenges and future directions, underscoring the importance of addressing key issues in the field. With this review, we encourage researchers to further develop exosome-based drugs for clinical application, as such drugs may be among the most promising next-generation therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the latest few reviews not systematically review the progress made in cancer treatment, nor do they clarify how exosome-based therapies could pave the way for future personalized medicine. Furthermore, they do not provide an in-depth analysis of the challenges that exosomes still face in cancer therapy, or the measures required to overcome them [14, 15].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
Self-citationToxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation
Yang, Z., Shi, J., Xie, J., Wang, Y., Sun, J., Liu, T., Zhao, Y., Zhao, X., Wang, X., Ma, Y., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0485-1 · Cited by 744
Self-citationTian, T., Zhu, Y.-L., Zhou, Y.-Y., Liang, G.-F., Wang, Y.-Y., Hu, F.-H., & Xiao, Z.-D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.588046 · Cited by 726
Self-citationYim, N., Ryu, S.-W., Choi, K., Lee, K. R., Lee, S., Choi, H., Kim, J., Shaker, M. R., Sun, W., Park, J.-H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12277 · Cited by 578
Self-citationIntradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy
You, Y., Tian, Y., Yang, Z., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Cao, J., Hsu, W.-H., Liu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00989-w · Cited by 258
Inhalable dry powder mRNA vaccines based on extracellular vesicles
Popowski, K. D., Moatti, A., Scull, G., Silkstone, D., Lutz, H., López de Juan Abad, B., George, A., Belcher, E., Zhu, D., Mei, X., et al. (2022) · Matter · doi:10.1016/j.matt.2022.06.012 · Cited by 218
Iyaswamy, A., Thakur, A., Guan, X.-J., Krishnamoorthi, S., Fung, T. Y., Lu, K., Gaurav, I., Yang, Z., Su, C.-F., Lau, K.-F., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01657-4 · Cited by 134
Liu, X., Cao, Z., Wang, W., Zou, C., Wang, Y., Pan, L., Jia, B., Zhang, K., Zhang, W., Li, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12857 · Cited by 132
Wu, S., Yun, J., Tang, W., Familiari, G., Relucenti, M., Wu, J., Li, X., Chen, H., & Chen, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c03050 · Cited by 102
Research works printed but not linked: 104
- Din, F. U. et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed. 12, 7291–7309 (2017). · DOI
- Domingues, C. et al. Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology. ACS Nano 16, 9994–10041 (2022). · DOI · Paper page
- Yang, F., Xue, J., Wang, G. & Diao, Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Front. Pharmacol. 13, 999404 (2022). · DOI
- Alshammari, B. H. et al. Organic and inorganic nanomaterials: fabrication, properties and applications. RSC Adv. 13, 13735–13785 (2023). · DOI
- Egbuna, C. et al. Toxicity of nanoparticles in biomedical application: nanotoxicology. J. Toxicol. 2021, 9954443 (2021). · DOI
- Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021). · DOI · Paper page
- Kim, J., Li, S., Zhang, S. & Wang, J. Plant-derived exosome-like nanoparticles and their therapeutic activities. Asian J. Pharm. Sci. 17, 53–69 (2022). · DOI
- Chen, H. et al. Exosomes, a new star for targeted delivery. Front. Cell Dev. Biol. 9, 751079 (2021). · DOI
- Ortega, A., Martinez-Arroyo, O., Forner, M. J. & Cortes, R. Exosomes as drug delivery systems: endogenous nanovehicles for treatment of systemic lupus erythematosus. Pharmaceutics 13 https://doi.org/10.3390/pharmaceutics13010003 (2020). · DOI
- Han, Y. et al. Overview and update on methods for cargo loading into extracellular vesicles. Processes 9 https://doi.org/10.3390/pr9020356 (2021). · DOI
- Jeppesen, D. K., Zhang, Q., Franklin, J. L. & Coffey, R. J. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol. 33, 667–681 (2023). · DOI · Paper page
- Willms, E., Cabanas, C., Mager, I., Wood, M. J. A. & Vader, P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 9, 738 (2018). · DOI
- Butler, J. T., Abdelhamed, S. & Kurre, P. Extracellular vesicles in the hematopoietic microenvironment. Haematologica 103, 382–394 (2018). · DOI
- EL Andaloussi, S., Mager, I., Breakefield, X. O. & Wood, M. J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347–357 (2013). · DOI · Paper page
- Liangsupree, T., Multia, E. & Riekkola, M. L. Modern isolation and separation techniques for extracellular vesicles. J. Chromatogr. A 1636, 461773 (2021). · DOI
- Witwer, K. W. & Thery, C. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. J. Extracell. Vesicles 8, 1648167 (2019). · DOI
- Minciacchi, V. R., Freeman, M. R. & Di Vizio, D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin. Cell Dev. Biol. 40, 41–51 (2015). · DOI
- Grant, B. D. & Donaldson, J. G. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 10, 597–608 (2009). · DOI · Paper page
- Xie, S., Zhang, Q. & Jiang, L. Current knowledge on exosome biogenesis, cargo-sorting mechanism and therapeutic implications. Membranes 12 https://doi.org/10.3390/membranes12050498 (2022). · DOI · Paper page
- Nolte-‘t Hoen, E., Cremer, T., Gallo, R. C. & Margolis, L. B. Extracellular vesicles and viruses: are they close relatives? Proc. Natl Acad. Sci. USA 113, 9155–9161 (2016). · DOI
- Mulcahy, L. A., Pink, R. C. & Carter, D. R. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles https://doi.org/10.3402/jev.v3.24641 (2014). · DOI · Paper page
- Joshi, B. S., de Beer, M. A., Giepmans, B. N. G. & Zuhorn, I. S. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano 14, 4444–4455 (2020). · DOI
- Polanco, J. C., Hand, G. R., Briner, A., Li, C. & Gotz, J. Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. Acta Neuropathol. 141, 235–256 (2021). · DOI
- Purushothaman, A. et al. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J. Biol. Chem. 291, 1652–1663 (2016). · DOI
- Hazawa, M. et al. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. Biochem. Biophys. Res. Commun. 446, 1165–1171 (2014). · DOI
- Prada, I. & Meldolesi, J. Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. Int. J. Mol. Sci. 17 https://doi.org/10.3390/ijms17081296 (2016). · DOI
- Krylova, S. V. & Feng, D. The machinery of exosomes: biogenesis, release, and uptake. Int. J. Mol. Sci. 24 https://doi.org/10.3390/ijms24021337 (2023). · DOI · Paper page
- Cecchin, R., Troyer, Z., Witwer, K. & Morris, K. V. Extracellular vesicles: the next generation in gene therapy delivery. Mol. Ther. 31, 1225–1230 (2023). · DOI
- Liang, Y. et al. Cell-derived nanovesicle-mediated drug delivery to the brain: principles and strategies for vesicle engineering. Mol. Ther. 31, 1207–1224 (2023). · DOI · Paper page
- Luan, X. et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017). · DOI
- Gorshkov, A., Purvinsh, L., Brodskaia, A. & Vasin, A. Exosomes as natural nanocarriers for RNA-based therapy and prophylaxis. Nanomaterials 12 https://doi.org/10.3390/nano12030524 (2022). · DOI
- Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21–39 (2008). · DOI · Paper page
- Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021). · DOI · Paper page
- Cao, Z. et al. Encapsulation of nano-bortezomib in apoptotic stem cell-derived vesicles for the treatment of multiple myeloma. Small e2301748 https://doi.org/10.1002/smll.202301748 (2023). · DOI · Paper page
- Lu, J. et al. Rejuvenation of tendon stem/progenitor cells for functional tendon regeneration through platelet-derived exosomes loaded with recombinant Yap1. Acta Biomater. 161, 80–99 (2023). · DOI
- Banach, M., Fabian, P., Stapor, K., Konieczny, L. & Roterman, A. I. Structure of the hydrophobic core determines the 3D protein structure-verification by single mutation proteins. Biomolecules 10 https://doi.org/10.3390/biom10050767 (2020). · DOI
- Kalinowska, B., Banach, M., Wisniowski, Z., Konieczny, L. & Roterman, I. Is the hydrophobic core a universal structural element in proteins? J. Mol. Model 23, 205 (2017). · DOI
- Jiao, Y. et al. Tumor cell-derived extracellular vesicles for breast cancer specific delivery of therapeutic P53. J. Control Release 349, 606–616 (2022). · DOI
- Liu, C. et al. An inhalable hybrid biomimetic nanoplatform for sequential drug release and remodeling lung immune homeostasis in acute lung injury treatment. ACS Nano 17, 11626–11644 (2023). · DOI
- Han, Y. et al. Extracellular vesicle-encapsulated CC16 as novel nanotherapeutics for treatment of acute lung injury. Mol. Ther. 31, 1346–1364 (2023). · DOI
- Nie, M., Huang, D., Chen, G., Zhao, Y. & Sun, L. Bioadhesive microcarriers encapsulated with IL-27 high expressive MSC extracellular vesicles for inflammatory bowel disease treatment. Adv. Sci. 10, e2303349 (2023). · DOI
- Jung, J. W. et al. Liver-originated small extracellular vesicles with TM4SF5 target brown adipose tissue for homeostatic glucose clearance. J. Extracell Vesicles 11, e12262 (2022). · DOI
- Salazar-Puerta, A. I. et al. Engineered extracellular vesicles derived from dermal fibroblasts attenuate inflammation in a murine model of acute lung injury. Adv. Mater. 35, e2210579 (2023). · DOI
- Gao, L. et al. Wnt3a-loaded extracellular vesicles promote alveolar epithelial regeneration after lung injury. Adv. Sci. 10, e2206606 (2023). · DOI
- Liu, W., Ota, M., Tabushi, M., Takahashi, Y. & Takakura, Y. Development of allergic rhinitis immunotherapy using antigen-loaded small extracellular vesicles. J. Control Release 345, 433–442 (2022). · DOI
- Wang, L. et al. Engineered cytokine-primed extracellular vesicles with high PD-L1 expression ameliorate type 1 diabetes. Small e2301019 https://doi.org/10.1002/smll.202301019 (2023). · DOI
- Liu, X. et al. Kidney tubular epithelial cells control interstitial fibroblast fate by releasing TNFAIP8-encapsulated exosomes. Cell Death Dis. 14, 672 (2023). · DOI
- Zhou, X. et al. Intranasal delivery of BDNF-loaded small extracellular vesicles for cerebral ischemia therapy. J. Control Release 357, 1–19 (2023). · DOI
- Milbank, E. et al. Small extracellular vesicle targeting of hypothalamic AMPKalpha1 promotes weight loss in leptin receptor deficient mice. Metabolism 139, 155350 (2023). · DOI
- Ramasamy, T., Munusamy, S., Ruttala, H. B. & Kim, J. O. Smart nanocarriers for the delivery of nucleic acid-based therapeutics: a comprehensive review. Biotechnol. J. 16, e1900408 (2021). · DOI · Paper page
- Lam, J. K., Chow, M. Y., Zhang, Y. & Leung, S. W. siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucleic Acids 4, e252 (2015). · DOI · Paper page
- Sun, Y. et al. In vivo self-assembled small RNA targets H19 lncRNA for the treatment of colorectal cancer. J. Control Release 358, 142–160 (2023). · DOI
- Lu, W. et al. Engineered NF-kappaB siRNA-encapsulating exosomes as a modality for therapy of skin lesions. Front. Immunol. 14, 1109381 (2023). · DOI
- Rong, Y. et al. Engineered extracellular vesicles for delivery of siRNA promoting targeted repair of traumatic spinal cord injury. Bioact. Mater. 23, 328–342 (2023).
- Respaud, R. et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs 6, 1347–1355 (2014). · DOI
- Elhissi, A. M., Faizi, M., Naji, W. F., Gill, H. S. & Taylor, K. M. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 334, 62–70 (2007). · DOI
- Han, Y. et al. Nebulization of extracellular vesicles: a promising small RNA delivery approach for lung diseases. J. Control Release 352, 556–569 (2022). · DOI
- Bontempi, G. et al. Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells. Cell Death Dis. 13, 965 (2022). · DOI
- Bheri, S. et al. Customized loading of microRNA-126 to small extracellular vesicle-derived vehicles improves cardiac function after myocardial infarction. ACS Nano 17, 19613–19624 (2023). · DOI · Paper page
- Elkhoury, K. et al. Hybrid extracellular vesicles-liposome incorporated advanced bioink to deliver microRNA. Biofabrication 14 https://doi.org/10.1088/1758-5090/ac8621 (2022). · DOI
- Hade, M. D., Suire, C. N. & Suo, Z. An effective peptide-based platform for efficient exosomal loading and cellular delivery of a microRNA. ACS Appl. Mater. Interfaces 15, 3851–3866 (2023). · DOI
- Yin, Z. et al. Injectable hyperbranched PEG crosslinked hyaluronan hydrogel microparticles containing mir-99a-3p modified subcutaneous ADSCs-derived exosomes was beneficial for long-term treatment of osteoarthritis. Mater. Today Bio 23, 100813 (2023). · DOI
- Adamus, T. et al. Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells. Mol. Ther. Nucleic Acids 27, 611–620 (2022). · DOI
- Mei, R. et al. “All-in-One” exosome engineering strategy for effective therapy of familial hypercholesterolemia. ACS Appl. Mater. Interfaces 14, 50626–50636 (2022). · DOI
- Yang, Z. et al. Improved extracellular vesicle-based mRNA delivery for familial hypercholesterolemia treatment. Theranostics 13, 3467–3479 (2023). · DOI
- Zhang, L. et al. Targeted elimination of senescent cells by engineered extracellular vesicles attenuates atherosclerosis in ApoE(-/-) mice with minimal side effects. Theranostics 13, 5114–5129 (2023). · DOI
- Camoes, S. P. et al. 3D-MSCs A151 ODN-loaded exosomes are immunomodulatory and reveal a proteomic cargo that sustains wound resolution. J. Adv. Res. 41, 113–128 (2022). · DOI · Paper page
- He, F. et al. Exosome-mediated delivery of RBP-J decoy oligodeoxynucleotides ameliorates hepatic fibrosis in mice. Theranostics 12, 1816–1828 (2022). · DOI
- Huang, X. et al. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy. J. Control Release 343, 107–117 (2022). · DOI · Paper page
- Born, L. J. et al. HOTAIR-loaded mesenchymal stem/stromal cell extracellular vesicles enhance angiogenesis and wound healing. Adv. Healthc. Mater. 11, e2002070 (2022). · DOI
- Fan, L. et al. Exosome-based mitochondrial delivery of circRNA mSCAR alleviates sepsis by orchestrating macrophage activation. Adv. Sci. 10, e2205692 (2023). · DOI
- Li, X. et al. Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart. Circulation 148, 405–425 (2023). · DOI
- Whitley, J. A. & Cai, H. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing. J. Extracell Vesicles 12, e12343 (2023). · DOI
- Stranford, D. M. et al. Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01142-x (2023). · DOI
- Reddy, S. K. et al. Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy. Theranostics 13, 2241–2255 (2023). · DOI
- Zhou, Y. et al. Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages. J. Control Release 364, 458–472 (2023). · DOI
- Chen, L. et al. Exosomes as drug carriers in anti-cancer therapy. Front. Cell Dev. Biol. 10, 728616 (2022). · DOI
- Kang, C. et al. Harnessing small extracellular vesicles for pro-oxidant delivery: novel approach for drug-sensitive and resistant cancer therapy. J. Control Release 365, 286–300 (2023). · DOI
- Rehman, F. U. et al. Heme oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy. J. Control Release 345, 696–708 (2022). · DOI
- Zhu, Z. et al. Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. J. Extracell Vesicles 11, e12255 (2022). · DOI
- Kim, Y. K. et al. Advantage of extracellular vesicles in hindering the CD47 signal for cancer immunotherapy. J. Control Release 351, 727–738 (2022). · DOI
- Al Faruque, H., Choi, E. S., Kim, J. H. & Kim, E. Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer. J. Control Release 347, 330–346 (2022). · DOI
- Tang, L. et al. Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy. Adv. Mater. e2303835 https://doi.org/10.1002/adma.202303835 (2023). · DOI
- Guo, R. et al. Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy. Eur. J. Nucl. Med. Mol. Imaging 50, 508–524 (2023). · DOI
- Nguyen Cao, T. G. et al. Bioreducible exosomes encapsulating glycolysis inhibitors potentiate mitochondria-targeted sonodynamic cancer therapy via cancer-targeted drug release and cellular energy depletion. Biomaterials 301, 122242 (2023). · DOI
- Nguyen Cao, T. G. et al. Brain endothelial cell-derived extracellular vesicles with a mitochondria-targeting photosensitizer effectively treat glioblastoma by hijacking the blood‒brain barrier. Acta Pharm. Sin. B 13, 3834–3848 (2023). · DOI
- Nguyen Cao, T. G. et al. Mitochondria-targeting sonosensitizer-loaded extracellular vesicles for chemo-sonodynamic therapy. J. Control Release 354, 651–663 (2023). · DOI · Paper page
- Nguyen Cao, T. G. et al. Engineered extracellular vesicle-based sonotheranostics for dual stimuli-sensitive drug release and photoacoustic imaging-guided chemo-sonodynamic cancer therapy. Theranostics 12, 1247–1266 (2022). · DOI
- Karimi, A., Majlesi, M. & Rafieian-Kopaei, M. Herbal versus synthetic drugs; beliefs and facts. J. Nephropharmacol. 4, 27–30 (2015).
- Zheng, X. et al. Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia. J. Control Release 353, 675–684 (2023). · DOI
- Gong, L. et al. CD44-targeting drug delivery system of exosomes loading forsythiaside A combats liver fibrosis via regulating NLRP3-mediated pyroptosis. Adv. Healthc. Mater. 12, e2202228 (2023). · DOI
- Yerneni, S. S. et al. Skin-targeted delivery of extracellular vesicle-encapsulated curcumin using dissolvable microneedle arrays. Acta Biomater. 149, 198–212 (2022). · DOI
- Gong, L. et al. An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy. J. Control Release 364, 672–686 (2023). · DOI
- Yang, J. et al. Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory. Biomaterials 302, 122303 (2023). · DOI
- Huang, R. et al. Plant exosomes fused with engineered mesenchymal stem cell-derived nanovesicles for synergistic therapy of autoimmune skin disorders. J. Extracell Vesicles 12, e12361 (2023). · DOI
- Huang, X. et al. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles. J. Nanobiotechnol. 21, 184 (2023). · DOI
- Gurung, S., Perocheau, D., Touramanidou, L. & Baruteau, J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun. Signal. 19, 47 (2021). · DOI
- Ngan, S. C., McCarthy, N. E. & Sze, S. K. pSILAC-based determination of cellular protein sorting into extracellular vesicles. Methods Mol. Biol. 2603, 43–58 (2023). · DOI
- Han, L. et al. Removing the stumbling block of exosome applications in clinical and translational medicine: expand production and improve accuracy. Stem Cell Res. Ther. 14, 57 (2023). · DOI
- Zhang, T. et al. CRISPR-Cas12a powered hybrid nanoparticle for extracellular vesicle aggregation and in-situ microRNA detection. Biosens. Bioelectron. 245, 115856 (2024). · DOI
- Reynolds, D. E., Galanis, G., Wang, Y. & Ko, J. Single extracellular vesicle analysis using droplet microfluidics. Methods Mol. Biol. 2689, 211–220 (2023). · DOI
- Meng, S. et al. MiR-141-3p-functionalized exosomes loaded in dissolvable microneedle arrays for hypertrophic scar treatment. Small e2305374 https://doi.org/10.1002/smll.202305374 (2023). · DOI
- He, J. et al. Exosomal targeting and its potential clinical application. Drug Deliv. Transl. Res. 12, 2385–2402 (2022). · DOI
- Whiteside, T. L. Tumor-derived exosomes and their role in cancer progression. Adv. Clin. Chem. 74, 103–141 (2016). · DOI
Cited by
Sorted by citations
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Metadata
- Authors
- Kim, H. I., Park, J., Zhu, Y., Wang, X., Han, Y., & Zhang, D.
- Venue
- Experimental & Molecular Medicine
- Published
- 2024-04-01
- Volume
- 56
- Issue
- 4
- Pages
- 836-849
- ISSN
- 2092-6413
- PMC
- PMC11059217
- Cited by
- 505
- References
- 12
- Language
- en
- Funders
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R00HL141685)
- Korea Health Industry Development Institute (HF23C0120)
- National Research Foundation of Korea (RS-2023-00213024)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review